Mingchen HealthLtd's (SZSE:002919) Five-year Earnings Growth Trails the 29% YoY Shareholder Returns
Mingchen HealthLtd's (SZSE:002919) Five-year Earnings Growth Trails the 29% YoY Shareholder Returns
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more than 100%. Long term Mingchen Health Co.,Ltd. (SZSE:002919) shareholders would be well aware of this, since the stock is up 254% in five years. Better yet, the share price has risen 14% in the last week.
購買一家公司的股票後的最壞成果(假設沒有槓桿)就是失去您投入的所有資金。但是當您選擇一個確實蓬勃發展的公司時,您可以創業板獲得超過100%的回報。一個很好的例子是HubSpot,Inc.(紐交所:HUBS),其股價在五年內上漲了249%。但上週下跌了6.6%。獲得100%以上的利潤。長期以來,名臣健康股份有限公司(SZSE:002919)的股東應該深知該公司的股價已上漲了254%,更好的是,股價在過去一個星期內上漲了14%。
After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.
在過去的一週之內,獲得的強勁收益是否表明了長期回報受到基本面的推動值得關注。
See our latest analysis for Mingchen HealthLtd
請參閱我們對名臣健康股份有限公司的最新分析。
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
儘管市場是一個強大的價格機制,但股票價格反映的不僅是潛在業務績效,還反映了投資者的情緒。 了解市場情緒隨時間的變化的一種方法是查看公司的股價與每股收益(EPS)之間的互動。
During the last half decade, Mingchen HealthLtd became profitable. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains.
在過去的5年裏,名臣健康股份有限公司實現了盈利。有時,盈利的起點可以是一個重要的拐點,可以預示着未來快速增長的盈利,進而可以證明股價的大幅上漲是合理的。
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
下面可以看到每股收益隨時間的變化情況(通過點擊圖像來查看確切數值)。
Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.
在購買或出售股票之前,我們始終建議仔細研究歷史增長趨勢,此處提供。
What About The Total Shareholder Return (TSR)?
那麼,股東總回報(TSR)呢?
We've already covered Mingchen HealthLtd's share price action, but we should also mention its total shareholder return (TSR). The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Its history of dividend payouts mean that Mingchen HealthLtd's TSR of 263% over the last 5 years is better than the share price return.
我們已經關注了名臣健康股份有限公司的股價走勢,但我們也應該提到其總股東回報(TSR)。TSR是一種回報計算,考慮現金股息的價值(假設所有股息都被再投資)以及任何打折的股本增發和股權分拆的計算價值。由於其股息支付歷史,名臣健康股份有限公司的TSR在過去5年中爲263%,優於股價回報。
A Different Perspective
不同的觀點
It's good to see that Mingchen HealthLtd has rewarded shareholders with a total shareholder return of 23% in the last twelve months. However, the TSR over five years, coming in at 29% per year, is even more impressive. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Mingchen HealthLtd you should know about.
值得欣慰的是,名臣健康股份有限公司在過去12個月中以總股東回報23%的回報獎勵了股東。但是,過去5年的TSR每年達到29%,更加令人印象深刻。雖然考慮到市場條件對股價的影響非常值得,但還有其他更重要的因素。例如,考慮風險。每個公司都有風險,我們也已經發現了名臣健康股份有限公司的1項警告信號,您應該知道。
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
如果您像我一樣,那麼您將不想錯過這份免費的增長公司清單,內部人正在購買。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。